Program overview
Idiopathic pulmonary fibrosis is a life-threatening disease characterized by the accumulation of fibroblasts which deposit extracellular matrix, causing progressive scarring of the alveolar parenchyma and eventual respiratory failure and death. The median survival is about 3 years from diagnosis. Although treatment can slow disease progression, there is no cure.
Patients with IPF can benefit from palliative care. Palliative care refers to any supportive care outside of direct disease treatment. In the case of IPF, it includes symptom management, oxygen supplementation, pulmonary rehabilitation, and psychosocial treatment, as well as advance care planning. Many patients, however, associate the term palliative care with end-of-life care and refuse it. Many clinicians do not offer it to their patients or they do not offer it until patients are near the end of life. Studies show that many patients with IPF are not receiving palliative care and, as a result, are experiencing a decreased quality of life. Clinicians should assess patient symptoms soon after diagnosis and provide the continuing supportive care their patients need.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Term of Offering
This activity was released on July 31, 2018 and is valid for one year. Requests for credit must be made no later than July 31, 2019.
Instructions for Obtaining Credit
In order to receive credit, participants must complete the online evaluation and post-test at the end of this program. Participants must also score at least a 70% on the post-test. Statements of credit will be issued upon completion of the evaluation and post-test.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure Declarations
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter | Reported Financial Relationship |
Jared Chiarchiaro, MD | Has nothing to disclose. |
Kevin Gibson, MD | Consultant: Bayer Pharmaceuticals |
Deborah Gillman, PhD | Spouse, Consultant: Sanofi Regeneron Pharmaceuticals |
Daniel Kass, MD | Consultant: Sanofi Regeneron Pharmaceuticals |
Kathleen O. Lindell,PhD, RN | Has nothing to disclose. |
Melissa Priore, RN | Has nothing to disclose. |
Laura Moreines, MSN, CRNP | Has nothing to disclose. |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Name of Planner or Manager | Reported Financial Relationship |
Global Academy for Medical Education, LLC planners and managers | Nothing to disclose |
The Postgraduate Institute for Medicine planners and managers | Nothing to disclose. |
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Commercial Support Statement
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Contact Information
The Postgraduate Institute for Medicine can be accessed at at www.pimed.com.